3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
28
Salivary Gland Neoplasms
2
Prostatic Neoplasms, Castration-Resistant
2
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Male Urogenital Diseases
2
Bulbo-Spinal Atrophy, X-Linked
2
Biochemically Recurrent Prostate Cancer
2
Adenocarcinoma
2
Urogenital Neoplasms
1
Urogenital Diseases
1
Sleep Initiation and Maintenance Disorders
1
Refractory or Relapsed Solid Tumors
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Neoplasms
1
High-Risk Localized Prostate Cancer
1
Granulosa cell tumor of the ovary
1
Genital Diseases, Male
1
Fatigue
1
Depression
1
Advanced Solid Tumor
1
Interventions
Specimen Handling
5
Biopsy
5
Whole-Body Irradiation
3
Mycophenolic Acid
3
Cyclosporine
3
Cyclophosphamide
3
Azacitidine
3
venetoclax
2
ruxolitinib
2
fludarabine phosphate
2
decitabine and cedazuridine drug combination
2
Sirolimus
2
Melphalan
2
Injections
2
Granulocyte Colony-Stimulating Factor
2
Decitabine
2
Busulfan
2
veliparib
1
tocilizumab
1
tagraxofusp
1
posaconazole
1
peginterferon alfa-2b
1
iadademstat
1
gilteritinib
1
fludarabine
1
fedratinib
1
axatilimab
1
Tranexamic Acid
1
Topotecan
1
Tacrolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myelodysplastic-Myeloproliferative Diseases
×
darolutamide
×
90 days
×
Clear all
No trials found.